Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + BCG vs BCG alone in high-risk NMIBC
NCT04149574Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2020
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of nivolumab in bladder cancer, sponsored by Bristol Myers Squibb. Started Jan 2020; status: terminated.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04149574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04149574.